
CureVac sells COVID-19, flu vaccines to GSK amid restructuring
Jul 04, 2024
Berlin [Germany], July 4: German biotech firm CureVac said on Wednesday that it is selling the rights to its mRNA influenza and COVID-19 vaccines to British pharmaceutical group GSK for up to 1.45 billion euros (1.56 billion U.S. dollars) as part of a group restructuring.
Read More ..